Department of Clinical and Experimental Medicine, Unit of Endocrinology University of Pisa, Pisa, Italy.
Department of Surgical and Medical Pathology, Unit of Pathology, University of Pisa, Pisa, Italy.
Endocrine. 2019 Sep;65(3):623-629. doi: 10.1007/s12020-019-01957-2. Epub 2019 Jul 5.
We investigated the expression of RET9 and RET51 isoforms in medullary (MTC), papillary (PTC) thyroid carcinoma, normal thyroid tissues, and pheochromocytoma (PHEO) to verify if these isoforms are present also in follicular thyroid cell-derived tissues, and if there is a differential expression of RET9 and RET51 in MTC.
Nineteen patients with MTC, 18 patients with PTC, 18 samples of contralateral normal thyroid tissues, and 5 cases of PHEO were included in this study. RET isoform expression was studied by real-time RT-PCR.
All MTCs and PHEOs were positive for RET9 and RET51. Fourteen/eighteen (77.7%) PTC cases were positive for RET9 and/or RET51, and four were positive for only one of the genes. In normal thyroid tissues, 3/18 (16.7%) cases were negative for both isoforms, 4/18 (22.2%) were positive for both, and 11/18 (61.1%) were positive for only one. RET isoforms were expressed at different levels in MTC, PHEO, PTC, and normal thyroid tissues: RET9 expression was higher in PHEO than in MTC, PTC, and normal thyroid tissues. RET9 expression was also higher in MTC than in PTC and normal thyroid tissues. No difference was observed between PTC and normal thyroid tissues. A similar pattern of expression was observed for RET51. In addition, RET51 was significantly more expressed than RET9 in MTC, while RET9 was the predominant isoform in PHEO.
Our study documented the expression of the RET9 and RET51 isoforms in normal thyroid and PTC tissues. RET9 and RET51 isoforms were also present in MTC and PHEO. RET51 expression was higher than RET9 expression in MTC, while there was no difference in the expression of these two isoforms in PTC and normal thyroid tissues. RET9 was more highly expressed than RET51 in PHEOs.
我们研究了 RET9 和 RET51 异构体在甲状腺髓样癌（MTC）、甲状腺乳头状癌（PTC）、正常甲状腺组织和嗜铬细胞瘤（PHEO）中的表达，以验证这些异构体是否也存在于滤泡性甲状腺细胞衍生组织中，以及 MTC 中 RET9 和 RET51 的表达是否存在差异。
本研究纳入了 19 例 MTC 患者、18 例 PTC 患者、18 例对侧正常甲状腺组织样本和 5 例 PHEO 患者。通过实时 RT-PCR 研究 RET 异构体的表达。
所有 MTC 和 PHEO 均为 RET9 和 RET51 阳性。14/18（77.7%）例 PTC 病例为 RET9 和/或 RET51 阳性，4 例仅为一种基因阳性。在正常甲状腺组织中，3/18（16.7%）例为两种异构体均阴性，4/18（22.2%）例为两种异构体均阳性，11/18（61.1%）例为仅一种异构体阳性。RET 异构体在 MTC、PHEO、PTC 和正常甲状腺组织中的表达水平不同：PHEO 中的 RET9 表达高于 MTC、PTC 和正常甲状腺组织。MTC 中的 RET9 表达也高于 PTC 和正常甲状腺组织。PTC 和正常甲状腺组织之间无差异。观察到 RET51 的表达模式相似。此外，在 MTC 中，RET51 的表达明显高于 RET9，而在 PHEO 中，RET9 是主要异构体。
本研究记录了 RET9 和 RET51 异构体在正常甲状腺和 PTC 组织中的表达。RET9 和 RET51 异构体也存在于 MTC 和 PHEO 中。在 MTC 中，RET51 的表达高于 RET9 的表达，而在 PTC 和正常甲状腺组织中，这两种异构体的表达没有差异。在 PHEO 中，RET9 的表达高于 RET51。
